MWA
ABMD

Marshall Wace Asia’s Abiomed Inc ABMD Stock Holding History

Marshall Wace Asia’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-47,537
Closed -$15.5M – 132
2018
Q4 		$15.5M Sell
47,537
-28,016
-37% -$9.73M 0.57% 53
2018
Q3 		$34M Buy
+75,553
New +$29.8M 1.15% 32

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Marshall Wace Asia's ABMD Position: Q1 2019 in Review

Marshall Wace Asia sold out of Abiomed Inc (ABMD) in Q1 2019, closing a stake of 47,537 shares — an estimated $15.5M sold.

Marshall Wace Asia first reported a position in ABMD in Q3 2018 and held it in 2 quarters. The position peaked at $34M in Q3 2018. 559 funds tracked by Wall St. Rank hold ABMD as of Q1 2019.

  • Marshall Wace Asia reported no remaining Abiomed Inc position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace Asia sold 47,537 Abiomed Inc shares in Q1 2019, an estimated $15.5M.
  • Marshall Wace Asia first reported a position in Abiomed Inc in Q3 2018 and held it in 2 quarters.
  • Marshall Wace Asia's Abiomed Inc position peaked at $34M in Q3 2018.
  • 559 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2019.

Based on Marshall Wace Asia's 13F filing for Q1 2019, filed 14 May 2019.